Top Markets
#1 Black Phoenix Black Phoenix +357.72%
#2 Islamic Coin Islamic Coin +158.16%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.42%
#6 Palladium Network Palladium Network +7.87%
#7 Pons Pons +7.21%
#8 Victoria VR Victoria VR +5.38%
#9 Movement Movement +5.24%
#10 Espresso Espresso +4.91%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Timber Pharmaceuticals, Inc. Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc.

TMBR
Rank in Stocks #42059
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.
Share Price
$0.0101
Last synced: 2023-12-26
Market Cap
$5.32K
Change (1 day)
741.67%
Change (1 year)
0.00%
Country
US
Trade Timber Pharmaceuticals, Inc. (TMBR)

Category

Healthcare
Revenue for Timber Pharmaceuticals, Inc. (TMBR)
Revenue in Aug 2026 TTM: 0
According to Timber Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Timber Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR